药物洗脱支架治疗移植肾动脉狭窄的安全性与疗效
回顾性分析2014年6月至2021年4月因临床显著移植肾动脉狭窄接受药物洗脱支架置入的12例患者共13处病变,中位随访9个月,支架内无狭窄一期通畅率76%、移植物存活率100%,3例再干预均因支架近端移植肾动脉扭结,作者建议支架置入时向髂外动脉延伸1-2 mm。
要点
- 药物洗脱支架治疗移植肾动脉狭窄短中期安全有效,移植物存活率100%。
- 支架内无狭窄一期通畅率76%,免于再干预率76%,一期辅助通畅率100%。
- 3例再干预均因支架近端移植肾动脉扭结,作者建议支架向髂外动脉延伸1-2 mm。
核心结论
- 本研究表明药物洗脱支架是移植肾动脉狭窄患者在短中期随访中安全有效的治疗方式。
- 由于药物洗脱支架置入后所有再干预均因支架近端移植肾动脉扭结所致,作者建议将支架向髂外动脉延伸1-2 mm。
研究设计与样本
- 回顾性综述2014年6月至2021年4月因临床显著移植肾动脉狭窄接受经皮腔内血管成形术联合药物洗脱支架置入的患者。
- 共纳入12例患者13处移植肾动脉狭窄,患者均表现为未控制高血压和/或不明原因移植物功能障碍。
- 收集患者人口学资料、手术细节和随访结局,主要终点为支架内一期通畅率和移植物存活率。
主要发现
- 中位年龄57岁(四分位距48-63岁),男性9例(70%),中位随访9个月(四分位距4-52个月)。
- 最常见合并症为高血压(100%)、冠心病(83%)和糖尿病,从 deceased donor 移植至干预的中位时间为5.8个月(四分位距3.5-6.7个月)。
- 移植肾动脉狭窄最常见位于近开口段(77%),9例(69%)在局部麻醉下、4例(31%)在全麻下手术,术中无并发症。
- 药物洗脱支架无狭窄一期通畅率和移植物存活率分别为76%和100%,免于再干预率和一期辅助通畅率分别为76%和100%。
- 3例再干预均因支架近端移植肾动脉扭结所致,通过将支架向近端延伸1-2 mm至髂外动脉治疗,中位再干预时间0.9个月(范围0.23-2个月),无入路相关并发症。
关键数值与推荐
- 药物洗脱支架无狭窄一期通畅率76%,移植物存活率100%。
- 免于再干预率76%,一期辅助通畅率100%。
- 中位支架直径4.5 mm(四分位距4-5 mm),中位支架长度15 mm(四分位距15-18 mm)。
- 手术采用二氧化碳血管造影联合最少碘对比剂(中位3 mL)。
临床怎么用
- 作者建议药物洗脱支架置入时向髂外动脉延伸1-2 mm,以处理支架近端移植肾动脉扭结导致的再狭窄。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transplant renal artery stenosis (TRAS) after renal transplantation is a common cause of graft dysfunction and failure. Endovascular intervention in the form of percutaneous transluminal angioplasty (PTA) and stenting has rapidly become the dominant treatment modality for the TRAS. There is a paucity of clinical data on the use of drug-eluting stent (DES) for TRAS. We investigated the outcomes of patients with clinically significant TRAS undergoing DES placement. METHODS: A retrospective review of patients with clinically significant TRAS undergoing PTA with DES placement from June 2014 to April 2021 was conducted. Patients treated for TRAS exhibited uncontrolled hypertension and/or unexplained allograft dysfunction. Patient demographics, procedural details, and follow-up outcomes were collected. Primary endpoints were the in-stent primary patency and graft survival. Secondary endpoints were freedom from reintervention, primary-assisted patency, and access-related complications. RESULTS: Thirteen TRAS in 12 patients with graft function alteration were treated with DES. The median age was 57 years (interquartile range (IQR), 48-63 years), and 9 (70%) patients were male. The median follow-up was 9 months (IQR, 4-52 months). The most common comorbidity was hypertension (100%), coronary artery disease (83%), and diabetes. The median time from deceased donor transplant to intervention was 5.8 months (IQR, 3.5-6.7 months). TRAS was most commonly found at the juxta-ostial segment (77%). The procedure was performed with carbon dioxide angiography with minimal amount of iodinated contrast (median, 3 mL) under local anesthesia in 9 (69%), and general anesthesia in 4 (31%) patients. The median stent diameter was 4.5 mm (IQR, 4-5 mm), and the median stent length was 15 mm (IQR, 15-18 mm). No intraoperative complications occurred. The rates of stenosis-free primary patency of the DES and graft survival were 76% and 100%, respectively. All 3 reinterventions for restenosis resulted from the kinking of the transplant renal artery proximal to the DES, which were treated by extending the stent more proximally 1-2 mm into the external iliac artery. There were no access-related complications. The median time to reintervention was 0.9 months (range, 0.23-2 months). Freedom from reintervention and primary-assisted patency were 76% and 100%, respectively. CONCLUSIONS: Our study demonstrates that DES is a safe and effective treatment modality in patients with TRAS at short to mid-term follow-up. As all reinterventions after DES were performed due to kinking of the transplant renal artery proximal to the stent, bridging of the DES 1-2 mm into the external iliac artery is recommended.
引用
- Chang H, Gelb BE, Stewart ZA, et al. Safety and Efficacy of Drug Eluting Stents for Treatment of Transplant Renal Artery Stenosis. Ann Vasc Surg. 2022. PMID: 35413413. doi:10.1016/j.avsg.2022.03.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。